Product Description
Erdanat 4mg Erdafitinib Tablet is an in-demand, affordable therapy for urothelial carcinoma, offering significant savings alongside superior clinical efficacy. Crafted by renowned brands BDR Pharmaceuticals and Natco Pharma Ltd., these lustrous, kingly white to off-white tablets deliver targeted inhibition of FGFR pathways. Each bottle contains 28 tablets, designed for oral administration to ensure patient convenience. Recommended strictly as a prescription-only medicine, Erdanat-4 guarantees quality and reliability, making it a trusted choice among healthcare professionals for effective cancer management in India and beyond.
Essential Features and Applications of Erdanat 4mg Erdafitinib Tablet
Erdanat 4mg Erdafitinib Tablet, featuring targeted FGFR inhibitor properties, is primarily used in the treatment of urothelial carcinoma, a type of bladder cancer. Recommended as a prescription-only medication, it is suitable for patients requiring advanced oral cancer therapy. The tablets are formulated for optimal absorption and packaged to preserve potency. This product is ideal for use under the supervision of oncology specialists, ensuring superior outcomes in eligible cancer patients.
Domestic Market Presence, Packaging, and Shipping Details of Erdanat-4
Erdanat 4mg Erdafitinib Tablet is widely available across the main domestic markets in India. The supply is estimated based on prescription demand and is shipped in secure bottles containing 28 tablets per unit. Reliable transport services ensure prompt delivery and safe handling across the country. Packaging is robust and tailored to protect the medication during transit and storage, allowing healthcare providers to receive products in optimal condition.
FAQ's of Erdanat 4mg Erdafitinib Tablet:
Q: How should Erdanat 4mg Erdafitinib Tablet be stored?
A: Store Erdanat 4mg Erdafitinib Tablet below 30C in a dry place, away from direct sunlight to maintain its efficacy until the expiration date.
Q: What is the main benefit of using Erdanat-4 for cancer therapy?
A: Erdanat-4 offers targeted inhibition of FGFR pathways, resulting in superior effectiveness for patients with urothelial carcinoma, and provides a more affordable, prescription-only option in cancer treatment.
Q: When is Erdanat-4 typically prescribed during cancer management?
A: Erdanat-4 is usually prescribed to adult patients diagnosed with urothelial carcinoma, based on a physician's evaluation of disease progression and suitability for targeted FGFR inhibitor therapy.
Q: Where is Erdanat 4mg Erdafitinib Tablet manufactured and supplied from?
A: Erdanat 4mg is manufactured and supplied by leading pharmaceutical companies in India, including BDR Pharmaceuticals and Natco Pharma Ltd.
Q: What is the recommended administration route for this medication?
A: The tablets are designed for oral use and should be taken as directed by a healthcare professional, following the prescribed dosage and duration.
Send Inquiry
Send Inquiry
Send SMS
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese